New hope for aggressive brain cancer? early trial of ERAS-801 begins

NCT ID NCT07089641

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activity using special scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ERAS-801 (an EGFR inhibitor drug taken by mouth)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very poor survival rates.
What could go wrong: This is a very early, small Phase 1 trial with only 10 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma astrocytoma (excluding glioblastoma) brain astrocytoma glioblastoma gliosarcoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA, IDH-WILDTYPE GLIOSARCOMA IDH WILDTYPE RECURRENT GLIOBLASTOMA IDH-WILDTYPE GLIOBLASTOMA RECURRENT ASTROCYTOMA RECURRENT GLIOBLASTOMA, IDH-WILDTYPE RECURRENT GLIOSARCOMA RESECTABLE ASTROCYTOMA RESECTABLE GLIOBLASTOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States
UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.